Cytokinetics | CYTK - Equity Capital And Reserves


Cytokinetics reported $-173.49M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Arca Biopharma USD 486.72M 17.72M Mar/2026
Bayer EUR 28.85B 2.9B Mar/2026
Biogen USD 18.85B 196.3M Jun/2026
Brainstorm Cell Therapeutics USD -11.01M 1.02M Mar/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Capricor Therapeutics USD 278.7M 27.09M Mar/2026
Cytokinetics USD -173.49M 653.08M Jun/2026
Eisai JPY 906.56B 7.57B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Exelixis USD 1.94B 225.57M Mar/2026
Geron USD 218.61M 10.49M Jun/2026
Halozyme Therapeutics USD 143.54M 76.09M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Ligand Pharmaceuticals USD 997.32M 19.89M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Novartis USD 41.95B 3.02B Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026